Paradigm Biocapital Advisors LP

Registered adviser

CIK

1855655

Location

NEW YORK, NY

Portfolio Value

Mid $5,340,558,022

Diversification

Diversified

Filing Date

Global Rank

#842 / 8,818 ▼ 33

Top Industry

Biotechnology 100.0%

3Y Alpha vs SPY

+3.5%

Period ended 4 months ago

Filed Aug 14, 2026 · 2mo

19 quarters · since Dec 2021

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Registered adviser

Form ADV roster, Oct 1, 2026

Form ADV adviser

CRD 312544

Roster of Oct 1, 2026

Regulatory AUM

$4,469,161,523

Main clients

Pooled investment vehicles (90% of AUM)

Private funds

2 funds · Hedge funds

Focus by fund count, roster of Oct 1, 2026

$4,076,406,790 gross assets

LEI

549300I649YOM8XI0E93

Private funds on Schedule D 7.B.(1)

As filed Sep 20, 2024; SEC's bulk Form ADV archive ends with 2024 filings.

$2,011,264,180 gross assets in 1 fund Hedge funds $2,011,264,180 (1)

Form ADV history

Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.

Rosters	Regulatory AUM	Main clients
Sep 2026 to Oct 2026	$4,469,161,523	Pooled investment vehicles (90%)
Apr 2026 to Aug 2026	$4,469,161,523	Pooled investment vehicles (90%)
Apr 2025 to Mar 2026	$3,054,844,396	Pooled investment vehicles (87%)
Apr 2024 to Mar 2025	$2,358,206,292	Pooled investment vehicles (85%)
May 2023 to Mar 2024	$933,207,592	Pooled investment vehicles (73%)
Apr 2023	$933,207,592	Pooled investment vehicles (73%)

3 earlier changes not shown.

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.

Style

Concentrated

The top 10 positions are 75.2% of the book (60%+)

Turnover

Medium turnover

76.4% over the last four quarters (30% to under 100%)

Horizon

Medium horizon

Value-weighted holding period 8.1 quarters (4 to under 12)

Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.3%; sector active share 90.9% against the combined 13F book's sector weights.

Over time 19 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

28 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026

Top Position

22.3%

+8.8 pts

Top 5

56.9%

+8.6 pts

Top 10

75.2%

+7.6 pts

HHI

951

Diversified+280

Portfolio Trend

19 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2026

Sector	% Portfolio	Value	Positions
Healthcare	100.0%	$5,340,558,022	28

Last Quarter's Activity

Export CSV

Jun 30, 2026 vs Mar 31, 2026

Added To

Positions the filer increased

12 positions

Ticker	Company	Δ Shares	Shares	Value
GMAB	Genmab A/S	+5,165,295	13,133,131	$360,767,108
VRDN	Viridian Therapeutics, Inc.\DE	+3,574,895	6,723,788	$123,515,985
EWTX	Edgewise Therapeutics, Inc.	+2,850,417	10,215,455	$415,053,936
TNGX	Tango Therapeutics, Inc.	+2,347,844	6,357,523	$198,736,168
SYRE	Spyre Therapeutics, Inc.	+1,883,512	3,840,778	$340,984,270
ASMB	Assembly Biosciences, Inc.	+888,497	1,553,748	$42,696,995
OLMA	Olema Pharmaceuticals, Inc.	+650,000	8,670,576	$108,468,905
—		+600,000	5,924,433	$731,667,476
—		+228,142	1,576,385	$209,233,581
TARS	Tarsus Pharmaceuticals, Inc.	+213,495	2,775,649	$174,699,348
BLTE	Belite Bio, Inc	+118,093	1,232,877	$189,844,564
INSM	INSMED Inc	+71,489	1,325,977	$141,375,667
No positions match the current search.

Trimmed

Positions the filer reduced

7 positions

Ticker	Company	Δ Shares	Shares	Value
PCVX	Vaxcyte, Inc.	−2,665,168	2,127,852	$123,692,036
LXEO	Lexeo Therapeutics, Inc.	−2,008,752	4,175,382	$19,436,403
ERAS	Erasca, Inc.	−842,702	9,550,000	$174,956,000
RVMD	Revolution Medicines, Inc.	−294,380	6,361,323	$1,191,348,571
EYPT	EyePoint, Inc.	−252,040	2,890,397	$41,332,677
TYRA	Tyra Biosciences, Inc.	−226,384	1,828,607	$58,405,707
ORKA	Oruka Therapeutics, Inc.	−175,790	2,144,526	$204,094,539
No positions match the current search.

New Positions

Positions the filer opened this quarter

7 positions

Ticker	Company	Shares	Value
ALNY	Alnylam Pharmaceuticals, Inc.	480,000	$144,494,400
MBX	MBX Biosciences, Inc.	2,508,015	$138,442,428
JBIO	Jade Biosciences, Inc.	2,857,405	$63,491,539
ACHV	Achieve Life Sciences, Inc.	4,951,856	$32,335,619
MPLT	MapLight Therapeutics, Inc.	685,852	$24,580,935
KARD	Kardigan, Inc.	900,000	$21,465,000
EDIT	Editas Medicine, Inc.	5,586,625	$18,100,665
No positions match the current search.

Sold Out

Positions the filer fully exited

14 positions

Ticker	Company	Shares	Value
—		5,774,016	$662,972,517
CNTA	Centessa Pharmaceuticals plc	3,574,048	$141,961,187
—		2,216,499	$116,853,827
CYTK	Cytokinetics Inc	1,480,857	$97,603,284
ABVX	Abivax S.A.	772,473	$86,014,868
MAZE	Maze Therapeutics, Inc.	2,744,399	$81,920,310
SRRK	Scholar Rock Holding Corp	1,226,080	$60,274,092
MIRM	Mirum Pharmaceuticals, Inc.	625,000	$57,737,500
MANE	Veradermics, Inc	525,000	$33,153,750
URGN	UroGen Pharma Ltd.	1,703,949	$30,637,003
GPCR	Structure Therapeutics Inc.	545,287	$26,282,833
ORIC	Oric Pharmaceuticals, Inc.	1,701,217	$21,554,419
BBOT	BridgeBio Oncology Therapeutics, Inc.	868,213	$7,770,506
KLRS	Kalaris Therapeutics, Inc.	700,000	$4,039,000
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

28 tracked positions · $5,340,558,022 total · filing declares 28 positions · $5,340,558,034 · as of Jun 30, 2026

All sectors Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
RVMD	Revolution Medicines, Inc. Healthcare	Reduced	6,361,323	-294,380	$1,191,348,571	+84.1%	10	$38.47	22.31%
		Added	5,924,433	+600,000	$731,667,476	+34.1%	13	unpriced	13.70%
EWTX	Edgewise Therapeutics, Inc. Healthcare	Added	10,215,455	+2,850,417	$415,053,936	+78.9%	10	$24.80	7.77%
GMAB	Genmab A/S Healthcare	Added	13,133,131	+5,165,295	$360,767,108	+68.8%	4	$27.30	6.76%
SYRE	Spyre Therapeutics, Inc. Healthcare	Added	3,840,778	+1,883,512	$340,984,270	+245.4%	8	$50.54	6.38%
		Added	1,576,385	+228,142	$209,233,581	+84.4%	10	$55.12	3.92%
ORKA	Oruka Therapeutics, Inc. Healthcare	Reduced	2,144,526	-175,790	$204,094,539	+79.3%	3	$29.67	3.82%
TNGX	Tango Therapeutics, Inc. Healthcare	Added	6,357,523	+2,347,844	$198,736,168	+136.9%	2	$17.91	3.72%
BLTE	Belite Bio, Inc Healthcare	Added	1,232,877	+118,093	$189,844,564	+6.8%	2	$166.74	3.55%
ERAS	Erasca, Inc. Healthcare	Reduced	9,550,000	-842,702	$174,956,000	+4.0%	9	$2.22	3.28%
TARS	Tarsus Pharmaceuticals, Inc. Healthcare	Added	2,775,649	+213,495	$174,699,348	−2.8%	11	$31.33	3.27%
ALNY	Alnylam Pharmaceuticals, Inc. Healthcare	NEW	480,000	NEW	$144,494,400	NEW	1	$301.61	2.71%
INSM	INSMED Inc Healthcare	Added	1,325,977	+71,489	$141,375,667	−31.1%	2	$151.98	2.65%
MBX	MBX Biosciences, Inc. Healthcare	NEW	2,508,015	NEW	$138,442,428	NEW	1	$34.93	2.59%
PCVX	Vaxcyte, Inc. Healthcare	Reduced	2,127,852	-2,665,168	$123,692,036	−55.6%	10	$55.28	2.32%
VRDN	Viridian Therapeutics, Inc.\DE Healthcare	Added	6,723,788	+3,574,895	$123,515,985	+100.5%	19	before history	2.31%
OLMA	Olema Pharmaceuticals, Inc. Healthcare	Added	8,670,576	+650,000	$108,468,905	−9.3%	14	$10.21	2.03%
JBIO	Jade Biosciences, Inc. Healthcare	NEW	2,857,405	NEW	$63,491,539	NEW	1	$20.86	1.19%
TYRA	Tyra Biosciences, Inc. Healthcare	Reduced	1,828,607	-226,384	$58,405,707	−25.8%	2	$32.37	1.09%
ASMB	Assembly Biosciences, Inc. Healthcare	Added	1,553,748	+888,497	$42,696,995	+131.3%	3	$29.36	0.80%
EYPT	EyePoint, Inc. Healthcare	Reduced	2,890,397	-252,040	$41,332,677	+2.0%	4	$12.73	0.77%
ACHV	Achieve Life Sciences, Inc. Healthcare	NEW	4,951,856	NEW	$32,335,619	NEW	1	$4.77	0.61%
VOR	Vor Biopharma Inc. Healthcare	Held	1,750,000	0	$32,217,500	+3.2%	3	$18.62	0.60%
MPLT	MapLight Therapeutics, Inc. Healthcare	NEW	685,852	NEW	$24,580,935	NEW	1	$28.76	0.46%
KARD	Kardigan, Inc. Healthcare	NEW	900,000	NEW	$21,465,000	NEW	1	unpriced	0.40%
LXEO	Lexeo Therapeutics, Inc. Healthcare	Reduced	4,175,382	-2,008,752	$19,436,403	−45.2%	3	$8.66	0.36%
EDIT	Editas Medicine, Inc. Healthcare	NEW	5,586,625	NEW	$18,100,665	NEW	1	$2.92	0.34%
IVA	Inventiva S.A. Healthcare	Held	4,000,000	0	$15,120,000	−31.9%	3	$4.65	0.28%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.